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Abstract
Background: Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is
interferon alpha plus ribavirin combination therapy (IFN a/ribavirin) and pegylated interferon plus ribavirin (PegIFN/
ribavirin). PegIFN/ribavirin has increased rate of sustained virological response than standard IFN a/ribavirin therapy.
Objective of current study was to analyze rate of early and delayed response to antiviral treatment as well as rate
of relapse response in patients following standard treatment IFN a/ribavirin and in patients following pegylated
interferon treatment.
Methods: Baseline serum samples of 153 patients enrolled for IFN a/ribavirin and 50 patients for PegIFN/ribavirin
were collected. After total RNA extraction, genotyping was and HCV RNA viral load was done. Subsequently HCV
RNA viral load was estimated at 4 weeks of treatment, at 12 weeks, at 24 or 48 weeks and finally after 6 months
follow up period. All the data was statistically analyzed using fisher’s exact test.
Results: Total 86 patients out of 153 patients following conventional IFN a/ribavirin therapy completed treatment
and 69% of them showed Rapid Virological Response (RVR). Whereas 50 patients following PegIFN/ribavirin
treatment completed treatment and 80% of them achieved RVR. Total 64 out of 86 patients following IFN a/
ribavirin therapy completed follow up period and 53.5% of them achieved Sustainded Virologcal Response (SVR).
Forty-five out of total 50 patients who received PegIFN/ribavirin treatment completed 6 months follow up period
and among these 70% achieved SVR. SVR rates were significantly associated with RVR (p < 0.001), age (p < 0.001)
and gender (p < 0.01)
Conclusions: Rate of sustained virological response can be determined by factors like rapid virological response
and age since they share significant association with one another. More over rate of SVR was more prominent in
males than in females.
Background
Hepatitis C virus, causative agent of chronic liver disease
has affected approximately 175 million people world-
wide which make up to almost 3% of the world’sp o p u -
lations and 3 to 4 million new cases adds up to this
figure annually [1]. Chronic HCV infection progresses
towards more severe outcomes in the form of cirrhosis
and hepatocellular carcinoma (HCC) [2]. Since protec-
tive vaccine against HCV is not available therefore suc-
cessful treatment of HCV is much needed. The standard
therapy for HCV treatment consist of subcutaneous
intake of 3 MU/ml of IFN a three times per week [3]
plus oral intake of 10 mg/day/kg of the body weight of
ribavirin daily for 24 weeks [4]. This standard therapy is
not ideal as success rate is not hundred percent in all
patients. A modified version of treatment consists of
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virin, administered for 12 to 72 weeks [5].
Different people respond differently to this a-inter-
feron treatment regimen and various terminologies are
used for these responses to therapy. When HCV RNA
becomes undetectable (< 50 IU/ml) after treatment
completion, the response is characterized as end of
treatment response (ETR), treatment response is said to
be sustained virological response (SVR) if HCV RNA
remain undetectable at the end of follow up (6 months
post treatment completion), but if it reappears after 6
months of follow up period than it is termed as
relapsed. However patients with a detectable HCV RNA
throughout the treatment are non responders (NR) [6].
Another recently studied emerging predictor of treat-
ment response, rapid virological response (RVR), defined
as a negative HCV RNA after four weeks of antiviral
treatment [7,8]. A 2 log decrease in HCV RNA after 12
weeks of treatment is defined as early virological
response (EVR). Breakthrough response (BT) is the type
of response when HCV RNA remains undetectable dur-
ing the treatment but reappears before the end of treat-
ment [9-11].
Various viral and host related factors are responsible
for such diversity in responses. HCV genotype and the
pre-treatment viral load influence the antiviral response
rates and this rate is higher for genotype 2 and 3 than
for genotype 1 [12]. Genotype 3a that is reported as the
most respondent to combination therapy is the most
frequent HCV genotype circulating in Pakistan [13].
Another reported factor that determines the rate of SVR
i st h ep r e s e n c eo ra b s e n c eo fR V R[ 7 ] .A m o n gh o s t
related factors, age and sex are very important as
younger age and female sex decrease the risk of disease
progression [14]. Furthermore treatment response is
affected by age, as younger patients (age < 40 years) are
associated with significantly higher rate of SVR than
older aged patients [7].
There are studies that have analyzed the rate of
response to IFN-a plus ribavirin treatment in Pakistan
along with various factors that might predict rate of SVR
[7], however these studies do not describe the effect of
different treatment strategies such as standard IFN-a
plus ribavirin combination therapy and PegIFN plus riba-
virin therapy on treatment response. Therefore the aim
of this study was to study the effect of different factors
such as sex, age, pre-treatment viral load and genotype in
two groups of patients treated either with IFN-a plus
ribavirin or PegIFN plus ribavirin. This study would be
useful in tailoring the treatment according to the
patient’s demographic status and in establishing which
treatment should be followed for better results.
Methods
Patients Enrolled
Patient’s demographic data and samples were collected
from 203 patients with chronic HCV infection from July
2009 to July 2010 at Ghurki Trust Hospital Lahore. Out
of these 203 patients, 152 patients (first group) received
standard HCV treatment of Interferon (3 Million units
per ml) 3 injections per week and Ribavirin 10 mg/day/
kg of the body weight, While 50 patients (second group)
received pegylated interferon (PegIFN 80 million units
per ml) 1 injection per week and ribavirin (10 mg/day/
kg of the body weight). Patients infected by HCV geno-
types None-1 and HCV-1 (or with co-infection with
HCV-1) received therapy for 24 weeks and 48 weeks
respectively. Total 67 patients were excluded from final
data analysis of the study since they were either unwill-
ing to participate in the study at some stage, sara sam-
ples were insufficient or lacked the requested
information regarding demographic characteristics. All
the 136 eligible patients were anti-HCV ELISA and
serum HCV RNA positive.
Quantitative detection of HCV RNA
Serum samples were collected from enrolled patients
before treatment, during treatment (at 4 weeks and 12
weeks) and at the end of treatment. All the serum sam-
ples were analyzed for quantitative detection of HCV
RNA titer using SmartCycler II real time (Cephid, USA).
HCV Genotyping
HCV genotyping was done on pre-treatment sera sam-
ples using the genotyping method described previously
[15].
Patient’s monitoring
Patient’s viral load was evaluated before treatment at 1
month, 3 months, 6 months (non-1 genotypes), 12
months (HCV-1) and at month 6 post treatment. Unde-
tectable HCV RNA titer (< 250 IU/ml) after first month
and third month of treatment was described as RVR
and EVR response respectively. Undetectable HCV RNA
at month 3 of treatment but reappearance of HCV RNA
at end of treatment was defined as breakthrough
response (BTR). HCV RNA less than 250 IU/mL at 6
months of treatment was defined as end of treatment
response (ETR). Undetectable HCV RNA (< 250 IU/ml)
6 months after treatment cessation was defined as sus-
tained virological response (SVR). Patients with detect-
able HCV RNA throughout the treatment were
classified as non responders while ETR patients with
detectable HCV RNA after 12 months were defined as
relapsers.
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SPSS version 16.0 was used to analyze all variables (age,
sex, genotypes, pre-treatment viral load, type of treat-
ment, rate of response). Means with standard deviation
and percentage frequencies of variables were calculated
where needed. Significant association amongst variables
was analyzed by calculating p-value using Fisher’sE x a c t
t-test. P-value less than 0.05 were indicative of signifi-
cant association.
Results
Demographic and clinical characteristics
Figure 1 shows the patients disposition and treatment
response. Out of total 203 enrolled subjects, 104 were
males and 98 were females. All of the patients received
treatment except 67 patients who either could not com-
pleted treatment for 6 months or they were unwilling to
participate in the study therefore were excluded from
final data analysis. Total 136 patients received treatment
Figure 1 Patients disposition and treatment responses.
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months). Demographic and virological characteristics of
these studied patients are summarized in table 1. For
data analysis, these patients were divided into two
groups based on the type of treatment they received.
Table 2 indicates distribution of genotypes in enrolled
patients. Genotype 3a was the predominant (more than
81%) genotype in patients subjected to these two differ-
ent types of treatments. Genotype 3a was the predomi-
nant genotype in both the groups of patients. Total 86
o u to ft h e s e1 3 6p a t i e n t sr e c e i v e d3M U / m lo fI F N - a
administered thrice a week along with 10 mg/day/kg of
the body weight of ribavirin administered orally.
Remaining 50 patients were subjected to 80 MU/ml of
Pegylated IFN administered once a week along with
same ribavirin dose for recommended duration based
on its genotype. In first group patients, 64 patients com-
pleted 6 months post treatment follow up period
whereas 22 patients in this group did not cooperate in
the study by providing requested information after treat-
ment completion. Of the second group, 45 out of 50
patients completed the follow up period and only 5
patients lost interest in study.
HCV Treatment response analysis
Table 3 translates the effects of different variables such
as sex, age, genotypes, treatment type and pre-treatment
viral load on treatment responses. SVR rates were found
higher significantly higher (p < 0.01) in male patients
compared to female patients. No significant difference
was seen in RVR, EVR and BTR in both sexes. Treat-
ment response was different in different age groups. A
significantly higher (p < 0.01) SVR was seen for patients
less than 20 years (66.7%) and 21-30 years (76.2%)
patients groups. A low SVR rate (44.4%) was observed
for age group 50-60 years and above group. Similar
results were seen for other type of responses such as
R V R ,E V Ra n dB T Ri nd i f f e r e n ta g eg r o u p s .R a t eo f
treatment response was also analyzed HCV genotype-
wise. No significance difference was observed for RVR,
EVR, BTR and ETR. Even SVR rates were same in
infected patients by Non-1 (59.7%) or 1 & mixed geno-
types (58.3%). Rates of ETR and SVR in patients treated
with PegIFN and ribavirin was significantly higher than
in patients received IFN-a and ribavirin combination
therapy. Similarly relapse rates were found significantly
higher in patients treated with IFN-a and ribavirin ther-
apy than in patients treated with Pegylated IFN/ribavirin
therapy. Effect of pre-treatment viral load on the rate of
response rates was also studied. Patients having pre-
treatment viral load < 200,000 IU/ml showed a slightly
lower rate of ETR and SVR than patients having viral
titer > 200,000 IU/ml, however, the difference was not
significant (p 0.14).
Factors associated with SVR rates
Table 4 shows several factors that are associated signifi-
cantly with SVR rates that can be utilize before treat-
ment for the prediction of treatment outcome. Among
these RVR and age are the strongest predictors of treat-
ment destiny.
Discussion
Interferon (IFN) plus ribavirin is a routine treatment for
chronic HCV infection in Pakistan. It comprises 3 MIU
given thrice a week along with ribavirin 800 to1200 mg
administered per day. Previous data shows that rate of
SVR raises to 38-43% with standard IFN a plus ribavirin
therapy [16]. A modified version of treatment is PegIFN
a plus ribavirin, it is the current treatment depending
Table 1 Demographic and virological characteristics of
enrolled patients who completed the entire treatment
course (N = 136).
Characteristics Number (%)
Sex
Male N (%) 69 (50.7)
Female N (%) 67 (49.3)
Pre-treatment HCV RNA level
>200,000 IU/ml N (%) 112 (82.4)
<200,000 IU/ml N (%) 24 (17.6)
Genotypes N (%)
3a 111 (81.6)
3b 1 (0.7)
1a 6 (4.4)
3a/1a 4 (2.9)
3a/1b 2 (1.5)
2b 1 (0.7)
Un typable 11 (8.1)
Characteristics Age Range-years ± SD
Mean Age (Y) 17-60 ± 10.02
N: number; IU: International units; ml: millilitre; SD, standard deviation;
Table 2 Distribution of HCV genotypes in patients
subjected to different types of treatments (N = 136)
HCV Genotypes Treatment type
IFNa & RBV
(%)
PegIFN & RBV
(%)
3a 78(90.6) 33 (66)
3b None 1 (2)
1a 1 (1.2) 5 (10)
3a/1a None 4 (8)
3a/1b None 2 (4)
2b 1 (.7) none
Untypable 6 (6.9) 5 (10)
Total 86 50
HCV: hepatitis C virus; INF: interferon; Peg: pegylated; RBV: ribavirin
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initial virological response to therapy [17], however this
type of treatment is not common in Pakistan due to
high cost of treatment. It is administered only once a
week and have 10 times longer half life of plasma than
the conventional IFN [18].
In the current study we have checked several host and
viral factors on treatment outcome in patients who
received both types of therapies. According to the
results of our study, rate of SVR was significantly higher
(p < 0.01) in patients received pegylated interferon com-
pared to non-pegylated interferon. Despite of this high
rate of SVR, most of our patients received standard
IFN-a plus ribavirin therapy due to cost factor as the
pegylated interferon is at least 25 times expensive than
non-pegylated interferon therefore is beyond the reach
of poor people in underdeveloped country like Pakistan
[19]. It has already been reported that rate of SVR with
PegIFN-a and ribavirin is comparatively high with geno-
type 2 and 3 (80%) than genotype 1 or 4 (40-50%) [5].
Our study support the findings of Shin and colleagues
[20] that SVR rate is high in genotype 3 (a&b) compared
to HCV genotype 1a when the current standard therapy
is used for treatment of HCV. Shin and colleagues [20]
further reported in their study that genotype 1 is a risk
factor for relapse response. Our study confirmed this
observation of Shin and colleagues [20] as relapse
response was about two times higher in genotype 1
infected patients (40%) compared to relapse rates seen
in patients harbouring genotype 3 HCV infections. In
addition to cost, several side effects have also been
reported to be associated with PegIFN plus ribavirin
therapy such as depression and anemia [5] therefore
conventional IFN plus ribavirin remains the gold
Table 3 Rates of responses in different sexes, ages, genotypes, treatment types and viral titres (N = 136)
Factor Total Treated RVR (%) EVR (%) BTR (%) ETR (%) NR (%) SVR (%)
SEX
Male
Female
69
67
3(4.3)
2(2.9)
7(10.1)
6(8.9)
4(5.8)
6(8.9)
52(75.4)
48(71.6)
17(24.6)
19(28.3)
48(69.6)
33(49.3)
AGE-years
<20 6 0 0 0 5(83.3) 1(16.7) 4(66.7)
21-30 42 1(2.4) 4(9.5) 2(4.8) 35(83.3) 7(16.7) 32(76.2)
31-40 43 2(4.7) 6(13.9) 5(11.6) 28(65.1) 15(34.9) 21(48.8)
41-50 36 2(5.6) 2(5.6) 2(5.6) 27(75) 9(25) 19(52.8)
51-60 & above 9 0 1(11.1) 1(11.1) 5(55.6) 4(44.4) 4(44.4)
GENOTYPE
None-1 124 5(4) 12(9.7) 9(7.3) 92(74.2) 32(25.8) 74(59.7)
1 & Mixed 12 0 1(8.3) 1(8.3) 8(66.7) 4(33.3) 7(58.3)
TREATMENT
INF+RBV 86 4(4.7) 8(9.3) 10(11.6) 60(69.8) 26(30.2) 46(53.5)
PEGINF+RBV 50 1(2) 5(10) 0 40(80) 10(20) 35(70)
PRE-TREATMEN
VIRAL LOAD
<200 IU/mL 112 4(3.6) 13(11.6) 9(8) 81(72.3) 31(27.7) 65(58)
>200 IU/mL 24 1(4.2) 0 1(4.2) 19(79.1) 5(20) 16(66.7)
TOTAL 136 5(3.6) 13(9.6) 10(7.4) 100(73.5) 36(26.5) 81(59.6)
RVR: Rapid virological response; EVR: Early Virological response; BTR: Breakthrough response; ETR: End of treatment response; NR: Non-responders; SVR: Sustained
virological response; INF: Interferon; PEG-INF: Pegylated interferon; RBV: ribavirin; IU/International units
Table 4 Association of gender, pre treatment viral load,
RVR and age with rate of SVR in patients following HCV
antiviral treatment
Variable Treated SVR (N) SVR rate P value <
patients (%)
(N)
Gender
Male 69 48 69.6 0.01
Female 67 33 49.2
Pre treatment viral load
≤ 200,000 IU/ml
> 200,000 IU/ml 24 16 66.7 0.14 (NS)
112 65 58.0
RVR
Present 5 5 100 0.001
Absent 131 76 58
Age
≤ 30 years 48 36 75 0.001
> 30 years 88 44 50
RVR: rapid virological response; SVR: Sustain virological response; NS: Non-
significance; IU: International units
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veloped countries like Pakistan.
Age is another factor that might determine the treat-
ment response. It has been reported recently that
patient age greater than 50 years increases the risk of
relapse [19]. Our study supports this observation of
others as in our study, rate of relapsers increased as the
age progresses. Relapse rate was lowest (8.6%) in
patients with an age ranging from 20 to 30 years and
rose to 33.3% in patients with an age above 50 years.
SVR rate was 91.4% in patients with age less than 30
and decreased to 66.7% with an age above 50 years. Our
study further supports the idea that age must be consid-
ered as an important associated factor while recom-
mending treatment to chronic HCV patients since SVR
rate significantly differed between different age groups
(p-value < .05).
Recently Shin and co-workers (19) has reported a
higher base line titer (≥ 200,000 IU/ml) as an indepen-
dent risk factor for higher relapse rate. In yet another
study low pretreatment viral load was pointed out as
predictor of the achievement of improved SVR rate as
SVR was significantly higher in patients that had base-
line viral load less than 200,000 IU/ml [7]. However, we
were unable to observe such an association between
pre-treatment viral load and treatment response. Relapse
rate decreased to only 8.6% in our patients with baseline
viral titer lower than 200,000 IU/ml. However SVR rate
in patients with baseline viral titer in both cases (> or <
200,000 IU/ml did not significantly differed (p-value >
.05).
Another important prognostic factor of the attainment
of SVR is achievement of RVR. A significantly associa-
tion was seen between RVR and SVR in the current
study (p < .001) as our all patients who had RVR had
also achieved SVR. Unfortunately the observed RVR rate
is very low as only our 3.6% patients had this type of
rapid response at week 4 of treatment. The RVR
response has already been established as an important
predictor of SVR in more than 85% cases [7].
HCV infection progresses slowly in females than in
males [14]. Unlike to several other studies (7, 16), the
observed SVR rate was significantly higher in males
than in females (p < 0.01).
Conclusions
Our study with reference to previous studies confirms
younger age and rapid virological response as important
factors for the achievement of sustained virological
response. Our study further established that male
patients have a greater chance of achieving SVR
responses.
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